Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychopharmacology
  4. Volume 12, Issue 1
  5. Article
Volume 12, Issue 1
  • ISSN: 2211-5560
  • E-ISSN: 2211-5579

Abstract

Background

Following clinical trials on psilocybin for the treatment of pain, anxiety, and depression in patients with cancer, scientific interest emerged in its use for substance use disorders.

Methods

In this review of the literature, we summarize available trials looking at the use of psilocybin in addiction.

Results

One double-blind, randomized clinical trial looked at the effect of psilocybin on heavy drinking in adults diagnosed with alcohol dependence. Several trials are currently ongoing to assess psilocybin’s efficacy in the management of different substance use disorders. Otherwise, the current evidence is insufficient to derive any conclusions on the possible efficacy of psilocybin in substance use disorders.

Conclusions

More well-powered, blinded, randomized controlled trials are needed to investigate the possible therapeutic effects of psilocybin in addiction while identifying the appropriate conditions that promote its safe use.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpsp/10.2174/0122115560288779240628043307
2024-07-03
2025-03-13

  • From This Site

    /content/journals/cpsp/10.2174/0122115560288779240628043307
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. UNODC. World Drug Report 2021. 2021. Available From: https://www.unodc.org/unodc/data-and-analysis/wdr2021.html
  2. PAHO. The burden of drug use disorders in the Region of the Americas, 2000-2019. Noncommunicable Diseases and Mental Health Data Portal 2021. 2021. Available From: https://www.paho.org/en/noncommunicable-diseases-and-mental-health/noncommunicable-diseases-and-mental-health-data-34#:~:text=The%20burden%20of%20health%20loss,613.8%20DALYs%20per%20100%2C000%20population
  3. NIDA. COVID-19 & substance use. Research Topics 2022. 2022. Available From: https://nida.nih.gov/research-topics/comorbidity/covid-19-substance-use#:~:text=Researchers%20have%20 observed %20increases%20in,national%20emergency%20in%20March%202020
  4. LópezG. OrchowskiL.M. ReddyM.K. NargisoJ. JohnsonJ.E. A review of research-supported group treatments for drug use disorders.Subst. Abuse Treat. Prev. Policy20211615110.1186/s13011‑021‑00371‑034154619
     [Google Scholar]
  5. DouaihyA.B. KellyT.M. SullivanC. Medications for substance use disorders.Soc. Work Public Health2013283-426427810.1080/19371918.2013.75903123731419
     [Google Scholar]
  6. MaqboolM. Substance use disorder and availability of treatment options: An overview.J. Res. Health Sci.20191410
     [Google Scholar]
  7. de VeenB.T.H. SchellekensA.F.A. VerheijM.M.M. HombergJ.R. Psilocybin for treating substance use disorders?Expert Rev. Neurother.201717220321210.1080/14737175.2016.122083427684102
     [Google Scholar]
  8. BlackmanS. Chilling out: The cultural politics of substance consumption, youth and drug policy.UKMcGraw-Hill Education2004
     [Google Scholar]
  9. GurschlerI. The fourfold discovery of Mescaline (1896–1919).Monatshefte fuer Chem.20191502941947
     [Google Scholar]
  10. NuttD. Psychedelic drugs—a new era in psychiatry?Dialogues Clin. Neurosci.201921213914710.31887/DCNS.2019.21.2/dnutt31636488
     [Google Scholar]
  11. Garcia-RomeuA. KersgaardB. AddyP.H. Clinical applications of hallucinogens: A review.Exp. Clin. Psychopharmacol.201624422926810.1037/pha000008427454674
     [Google Scholar]
  12. NicholsD.E. Psychedelics.Pharmacol. Rev.201668226435510.1124/pr.115.01147826841800
     [Google Scholar]
  13. GrinspoonL. BakalarJ.B. Psychedelic drugs reconsidered.New YorkBasic Books1979
     [Google Scholar]
  14. BuschA.K. JohnsonW.C. L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug.Dis. Nerv. Syst.195011824124314793387
     [Google Scholar]
  15. RuckerJ.J.H. JelenL.A. FlynnS. FrowdeK.D. YoungA.H. Psychedelics in the treatment of unipolar mood disorders: A systematic review.J. Psychopharmacol.201630121220122910.1177/026988111667936827856684
     [Google Scholar]
  16. KrebsT.S. JohansenP.Ø. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials.J. Psychopharmacol.2012267994100210.1177/026988111243925322406913
     [Google Scholar]
  17. HallW. Why was early therapeutic research on psychedelic drugs abandoned?Psychol. Med.2022521263110.1017/S003329172100420734670633
     [Google Scholar]
  18. NuttD.J. KingL.A. PhillipsL.D. Drug harms in the UK: A multicriteria decision analysis.Lancet201037697521558156510.1016/S0140‑6736(10)61462‑621036393
     [Google Scholar]
  19. HonigE. In close vote, denver becomes 1st U.S. city to decriminalize psychedelic mushrooms. 2019. Available From: https://www.npr.org/sections/health-shots/2019/05/09/721660053/in-close-vote-denver-becomes-first-u-s-city-to-decriminalize-psychedelic-mushroo
  20. Kennedy M. Oakland city council effectively decriminalizes psychedelic mushrooms. 2019. Available From: https://www.npr.org/2019/06/05/730061916/oakland-city-council-effectively-decriminalizespsychedelic-mushrooms
  21. KaurH. Santa Cruz decriminalizes magic mushrooms and other natural psychedelics, making it the third US city to take such a step. 2020. Available From: https://edition.cnn.com/2020/01/30/us/santa-cruz-mushrooms-psychedelics-trnd/index.html
  22. GeigerH.A. WurstM.G. DanielsR.N. DARK classics in chemical neuroscience: Psilocybin.ACS Chem. Neurosci.20189102438244710.1021/acschemneuro.8b0018629956917
     [Google Scholar]
  23. KargboR.B. Psilocybin therapeutic research: The present and future paradigm.ACS Med. Chem. Lett.202011439940210.1021/acsmedchemlett.0c0004832292538
     [Google Scholar]
  24. HalberstadtA.L. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.Behav. Brain Res.20152779912010.1016/j.bbr.2014.07.01625036425
     [Google Scholar]
  25. MertensL.J. PrellerK.H. Classical psychedelics as therapeutics in psychiatry – current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders.Pharmacopsychiatry202154417619010.1055/a‑1341‑190733472250
     [Google Scholar]
  26. HalberstadtA.L. GeyerM.A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Neuropharmacology201161336438110.1016/j.neuropharm.2011.01.01721256140
     [Google Scholar]
  27. Erkizia-SantamaríaI. Alles-PascualR. HorrilloI. MeanaJ.J. OrtegaJ.E. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response.Biomed. Pharmacother.202215411361210.1016/j.biopha.2022.11361236049313
     [Google Scholar]
  28. MckennaD.J. RepkeD.B. LoL. PeroutkaS.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes.Neuropharmacology199029319319810.1016/0028‑3908(90)90001‑82139186
     [Google Scholar]
  29. WishartD.S. FeunangY.D. GuoA.C. DrugBank 5.0: A major update to the DrugBank database for 2018.Nucleic Acids Res.201846D1D1074D108210.1093/nar/gkx103729126136
     [Google Scholar]
  30. HaslerF. GrimbergU. BenzM.A. HuberT. VollenweiderF.X. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose?effect study.Psychopharmacology2004172214515610.1007/s00213‑003‑1640‑614615876
     [Google Scholar]
  31. VollenweiderF.X. Vollenweider-ScherpenhuyzenM.F.I. BäblerA. VogelH. HellD. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.Neuroreport19989173897390210.1097/00001756‑199812010‑000249875725
     [Google Scholar]
  32. KometerM. SchmidtA. BachmannR. StuderusE. SeifritzE. VollenweiderF.X. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.Biol. Psychiatry2012721189890610.1016/j.biopsych.2012.04.00522578254
     [Google Scholar]
  33. MadsenM.K. FisherP.M. BurmesterD. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.Neuropsychopharmacology20194471328133410.1038/s41386‑019‑0324‑930685771
     [Google Scholar]
  34. PassieT. SeifertJ. SchneiderU. EmrichH.M. The pharmacology of psilocybin.Addict. Biol.20027435736410.1080/135562102100000593714578010
     [Google Scholar]
  35. GriffithsR.R. JohnsonM.W. RichardsW.A. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.J. Psychopharmacol.2018321496910.1177/026988111773127929020861
     [Google Scholar]
  36. JohnsonM.W. GriffithsR.R. HendricksP.S. HenningfieldJ.E. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.Neuropharmacology201814214316610.1016/j.neuropharm.2018.05.01229753748
     [Google Scholar]
  37. LimT.H. WasywichC.A. RuygrokP.N. A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient.Intern. Med. J.201242111268126910.1111/j.1445‑5994.2012.02955.x23157524
     [Google Scholar]
  38. BorowiakK. Psilocin multiple intake resulted and in cardiotoxic effects.Acta Toxicologica2006141-2
     [Google Scholar]
  39. LoweH. ToyangN. SteeleB. The therapeutic potential of psilocybin.Molecules20212610294810.3390/molecules2610294834063505
     [Google Scholar]
  40. ClinicalTrials.gov. A double-blind trial of psilocybin-assisted treatment of alcohol dependence. 2014. Available From: https://clinicaltrials.gov/ct2/show/NCT02061293
  41. ClinicalTrials.gov. Clinical and mechanistic effects of psilocybin in alcohol addicted patients. 2019. Available From: https://clinical trials.gov/ct2/show/NCT04141501
  42. ClinicalTrials.gov. Psilocybin-assisted therapy for treatment of alcohol use disorder. 2022. Available From: https://clinical trials.gov/ct2/show/NCT05416229
  43. ClinicalTrials.gov. 5-HT2A agonist psilocybin in the treatment of tobacco use disorder. 2024. Available From: https://clinical trials.gov/ct2/show/NCT05452772
  44. ClinicalTrials.gov. Psilocybin for opioid use disorder in patients on methadone maintenance with ongoing opioid use. 2022. Available From: https://clinicaltrials.gov/ct2/show/NCT05242029
  45. ClinicalTrials.gov. Psilocybin-facilitated Treatment for Cocaine use. 2014. Available From: https://clinicaltrials.gov/ct2/show/NCT02037126
  46. ClinicalTrials.gov. Psilocybin treatment of major depressive disorder with co-occurring alcohol use disorder (PsiloMDDAUD). 2020. Available From: https://clinicaltrials.gov/ct2/show/NCT04620759
  47. ClinicalTrials.gov. Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial. 2020. Available From: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000829-55/DK
  48. MeinhardtM.W. PfarrS. FouquetG. Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism.Sci. Adv.2021747eabh239910.1126/sciadv.abh239934788104
     [Google Scholar]
  49. MeinhardtM.W. GüngörC. SkorodumovI. MertensL.J. SpanagelR. Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.Neuropsychopharmacology20204581316132210.1038/s41386‑020‑0694‑z32369828
     [Google Scholar]
  50. BogenschutzM.P. RossS. BhattS. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder.JAMA Psychiatry2022791095396210.1001/jamapsychiatry.2022.209636001306
     [Google Scholar]
  51. BogenschutzM.P. PodrebaracS.K. DuaneJ.H. Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder.Front. Pharmacol.2018910010.3389/fphar.2018.0010029515439
     [Google Scholar]
  52. BogenschutzM.P. ForcehimesA.A. PommyJ.A. WilcoxC.E. BarbosaP.C.R. StrassmanR.J. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study.J. Psychopharmacol.201529328929910.1177/026988111456514425586396
     [Google Scholar]
  53. PisanoV.D. PutnamN.P. KramerH.M. FranciottiK.J. HalpernJ.H. HoldenS.C. The association of psychedelic use and opioid use disorders among illicit users in the United States.J. Psychopharmacol.201731560661310.1177/026988111769145328196428
     [Google Scholar]
  54. JonesG. RicardJ.A. LipsonJ. NockM.K. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.Sci. Rep.20221214099910.1038/s41598‑022‑08085‑435393455
     [Google Scholar]
  55. Garcia-RomeuA. DavisA.K. ErowidE. ErowidF. GriffithsR.R. JohnsonM.W. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey.Front. Psychiatry20201095510.3389/fpsyt.2019.0095532038317
     [Google Scholar]
  56. ArgentoE. SociasM.E. HayashiK. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.Int. J. Drug Policy202210010351810.1016/j.drugpo.2021.10351834758431
     [Google Scholar]
  57. JonesG.M. NockM.K. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study.Sci. Rep.2022121257410.1038/s41598‑022‑06580‑235173246
     [Google Scholar]
  58. JohnsonM.W. Garcia-RomeuA. CosimanoM.P. GriffithsR.R. Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction.J. Psychopharmacol.2014281198399210.1177/026988111454829625213996
     [Google Scholar]
  59. Garcia-RomeuA. GriffithsR. JohnsonM. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Curr. Drug Abuse Rev.20157315716410.2174/187447370866615010712133125563443
     [Google Scholar]
  60. JohnsonM.W. Garcia-RomeuA. GriffithsR.R. Long-term follow-up of psilocybin-facilitated smoking cessation.Am. J. Drug Alcohol Abuse2017431556010.3109/00952990.2016.117013527441452
     [Google Scholar]
  61. NooraniT. Garcia-RomeuA. SwiftT.C. GriffithsR.R. JohnsonM.W. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.J. Psychopharmacol.201832775676910.1177/026988111878061229938565
     [Google Scholar]
  62. JonesG. LipsonJ. NockM.K. Associations between classic psychedelics and nicotine dependence in a nationally representative sample.Sci. Rep.20221211057810.1038/s41598‑022‑14809‑335732796
     [Google Scholar]
  63. SchlagA.K. AdayJ. SalamI. NeillJ.C. NuttD.J. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.J. Psychopharmacol.202236325827210.1177/0269881121106910035107059
     [Google Scholar]
  64. JohnsonM.W. GriffithsR.R. Potential therapeutic effects of psilocybin.Neurotherapeutics201714373474010.1007/s13311‑017‑0542‑y28585222
     [Google Scholar]
  65. NuttD. ErritzoeD. Carhart-HarrisR. Psychedelic psychiatry’s brave new world.Cell20201811242810.1016/j.cell.2020.03.02032243793
     [Google Scholar]
  66. GoldbergS.B. PaceB.T. NicholasC.R. RaisonC.L. HutsonP.R. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.Psychiatry Res.202028411274910.1016/j.psychres.2020.11274931931272
     [Google Scholar]
  67. da CostaS.C. OesterleT. RummansT.A. RichelsonE. GoldM. Psychedelic drugs for psychiatric disorders.J. Neurol. Sci.202244012033210.1016/j.jns.2022.12033235841696
     [Google Scholar]
/content/journals/cpsp/10.2174/0122115560288779240628043307
Loading
Psilocybin in the Management of Substance Use Disorders: A Summary of Current Evidence
Current Psychopharmacology 12, E030724231519 (2024); https://doi.org/10.2174/0122115560288779240628043307
/content/journals/cpsp/10.2174/0122115560288779240628043307
/content/journals/cpsp/10.2174/0122115560288779240628043307
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): addiction; hallucinogen; premature mortality; Psilocybin; psychedelic; substance use disorder

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test